Regeneron Pharmaceuticals, Inc. with price, financials, news flow, and insider context in one page.
Regeneron Pharmaceuticals, Inc. is being tracked here through price action, operating context, and headline flow. This public page covers the latest market move, where REGN sits inside Healthcare and Biotechnology, and the key financial markers that matter before moving into a fuller research workflow.
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
This page is structured for research context, not a trade call. It gives you a clean read on where REGN sits in its range, what the last few quarters look like, and which headlines are shaping attention.
For position sizing, alerts, saved watchlists, and deeper analysis workflows, the next step is the logged-in Meridian workspace.
| Quarter | Revenue | Net income | Free cash flow |
|---|---|---|---|
| Q1 2026 | 3.61B | 727.2M | 799.4M |
| Q4 2025 | 3.88B | 844.6M | 880M |
| Q3 2025 | 3.75B | 1.46B | 1.37B |
| Q2 2025 | 3.68B | 1.39B | 737.6M |
See the next report date, earnings cadence, and reporting context.
Open a side-by-side comparison page to frame valuation and growth.
Read open desk notes tied to sectors, macro themes, and active names.
Learn the framework behind valuation, momentum, and risk before you act.
Regeneron Pharmaceuticals, Inc. (REGN) — questions investors ask
What is the current stock price of Regeneron Pharmaceuticals, Inc. (REGN)?
Regeneron Pharmaceuticals, Inc. (REGN) is trading at $632.90, up 2.06% in the latest session. The live price and one-year chart on this page update through the trading day.
What is Regeneron Pharmaceuticals, Inc.'s market capitalization?
Regeneron Pharmaceuticals, Inc. has a market capitalization of about 66.35B, derived from the latest share price and shares outstanding.
When is Regeneron Pharmaceuticals, Inc.'s next earnings date?
Regeneron Pharmaceuticals, Inc. is next expected to report earnings on Jul 30, 2026. The REGN earnings page tracks the estimate and reporting history.
What is Regeneron Pharmaceuticals, Inc.'s P/E ratio?
Regeneron Pharmaceuticals, Inc. trades at a forward price-to-earnings ratio of 11.77 — one measure of how the market is pricing its future earnings.
What is REGN's 52-week trading range?
Over the past 52 weeks, REGN has traded between $518.90 and $821.11.
What sector is Regeneron Pharmaceuticals, Inc. in?
Regeneron Pharmaceuticals, Inc. operates in the Healthcare sector, within the Biotechnology industry.
Does Regeneron Pharmaceuticals, Inc. pay a dividend?
Regeneron Pharmaceuticals, Inc. currently carries a dividend yield of about 59.0%.
What is the analyst price target for REGN?
The mean analyst price target for REGN is $833.31, with an overall analyst view of Buy.
A public stock page should answer the first research questions before asking for a signup.
This REGN page is designed for public research utility. You can read the latest session move, check the one-year chart, review a compact financial table, scan recent headlines, and compare adjacent names without immediately moving into a gated dashboard.
The logged-in Meridian workflow goes further with saved watchlists, deeper analysis, alert routing, and recurring review systems. The public layer is meant to be credible and indexable on its own, not a hollow teaser page.